BRCA2 and cancer: Genetic or epigenetic inactivation of MCM8-9 is a new mechanism by which cancers can blunt the HR repair pathway, and as in cancers with mutations in BRCA1 or BRCA2, cancers that inactivate MCM8-9 are susceptible to chemotherapy agents that target cells with blunted HR.